Prog Retin Eye Res:中国学者第一期刊发文探讨老年致盲眼病早期干预

2019-01-29 肖洁 科学网

日前,全球眼科领域顶级期刊《Progress in Retinal and Eye Research》(以下简称PRER)在线发表了中南大学爱尔眼科学院教授徐和平及其研究团队的论文《老化视网膜中的免疫调控》。该论文通过探讨老化过程中视网膜的免疫调控,寻求老年性退行性视网膜疾病的发病机理,尝试找到老年黄斑变性、糖尿病视网膜病变等眼病发病早期的干预手段,使致盲眼病患者在不可逆视觉损伤发生之前得到及时的

日前,全球眼科领域顶级期刊《Progress in Retinal and Eye Research》(以下简称PRER)在线发表了中南大学爱尔眼科学院教授徐和平及其研究团队的论文《老化视网膜中的免疫调控》。该论文通过探讨老化过程中视网膜的免疫调控,寻求老年性退行性视网膜疾病的发病机理,尝试找到老年黄斑变性、糖尿病视网膜病变等眼病发病早期的干预手段,使致盲眼病患者在不可逆视觉损伤发生之前得到及时的预防性治疗,从而攻克致盲眼病难以“早发现早干预”的问题。

这是徐和平第二次受邀在该杂志发表综述文章。其在2009年第一次发表的《老化视网膜中的亚炎症》已引用超430多次。该文首次在眼科领域提出了亚炎症(Para-inflammation)的概念,并阐述了其在老年黄斑变性发病过程中的作用,引发眼科学界广泛关注。

视网膜是人类眼球中一层柔软而透明的膜,当我们看东西时,物体的影像通过屈光系统,落在视网膜上。就像一架照相机里的感光底片,专门负责感光成像。一旦视网膜发生病变,如果没有得到及时、有效的治疗,将导致患者终生失明。

老年黄斑变性、青光眼、糖尿病视网膜病变是老年人常见的典型致盲性眼病,一旦患病致盲率远高于一般眼病,被称为“视力杀手”。随着年龄增长、机体的老化,发生这些退行性眼部疾病的风险不断增加。流行病学调查结果显示,我国60岁以上人群中,老年黄斑变性发病率已高达6%-11%,并随着年龄的增长而持续上升,总病患数量高达千万以上。

致盲性眼病危害极大,发病率却逐年走高,主要原因之一就是无法做到早发现早干预早治疗。以青光眼为例,资料显示,目前中国40岁以上人群青光眼患病率为2.3%,致盲率约30%。预计到2020年,我国将有2100万的青光眼患者,产生近630万盲人及超过1000万的视觉残障人士。然而,在对我国青光眼患者的调查中发现,该疾病的社会认知度仅为63%,有2/3的患者在初诊时已到了中晚期。这与人类至今未全面了解该类疾病发病机理有密切关系。

本次研究中,徐和平团队以眼免疫为主要切入点,深入探讨了衰老对视网膜免疫调节的影响,以及视网膜免疫赦免的稳态控制与老化条件下的亚炎症之间的关系。徐和平指出,下一步研究将结合爱尔的临床资源,寻求发现发病早期的异常,进一步了解老化是如何影响眼部免疫调控进而引发疾病,寻找老年黄斑变性、糖尿病视网膜病变等眼病发病早期的干预手段,使这些致盲眼病患者在不可逆视觉损伤发生之前得到及时治疗。

在徐和平看来,当今医学界所推崇的循证医学理念中,能否开展多中心研究是医学临床科研项目取得成果的关键因素之一。爱尔眼科在全球分布有400多家医院,对于开展大规模、多中心研究具有很大优势。

专家认为,徐和平此次研究相比九年前更进一步,从获得性免疫到固有免疫,从免疫豁免与局部免疫调控到系统性免疫调控,全面总结了近年来对免疫调控在视网膜老化与退行性疾病中作用的研究进展。

原始出处:

Mei Chen, Chang Luo, Jiawu Zhao, et.al. Immune regulation in the aging retina[J]. Progress in Retinal and Eye Research Available online 20 October 2018

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1668663, encodeId=d2d31668663a2, content=<a href='/topic/show?id=4929593e57f' target=_blank style='color:#2F92EE;'>#早期干预#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59375, encryptionId=4929593e57f, topicName=早期干预)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ab126374998, createdName=gao_jian4226, createdTime=Sun Apr 14 05:02:00 CST 2019, time=2019-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029876, encodeId=d57420298e614, content=<a href='/topic/show?id=fedde18245' target=_blank style='color:#2F92EE;'>#eye#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7182, encryptionId=fedde18245, topicName=eye)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Wed May 22 23:02:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913902, encodeId=fd87191390247, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sun Feb 10 07:02:00 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540519, encodeId=aedc1540519cd, content=<a href='/topic/show?id=fbbce2786cc' target=_blank style='color:#2F92EE;'>#眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72786, encryptionId=fbbce2786cc, topicName=眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b85c13256921, createdName=pps20023, createdTime=Thu Jan 31 06:02:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602110, encodeId=7fd71602110f7, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Thu Jan 31 06:02:00 CST 2019, time=2019-01-31, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1668663, encodeId=d2d31668663a2, content=<a href='/topic/show?id=4929593e57f' target=_blank style='color:#2F92EE;'>#早期干预#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59375, encryptionId=4929593e57f, topicName=早期干预)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ab126374998, createdName=gao_jian4226, createdTime=Sun Apr 14 05:02:00 CST 2019, time=2019-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029876, encodeId=d57420298e614, content=<a href='/topic/show?id=fedde18245' target=_blank style='color:#2F92EE;'>#eye#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7182, encryptionId=fedde18245, topicName=eye)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Wed May 22 23:02:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913902, encodeId=fd87191390247, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sun Feb 10 07:02:00 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540519, encodeId=aedc1540519cd, content=<a href='/topic/show?id=fbbce2786cc' target=_blank style='color:#2F92EE;'>#眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72786, encryptionId=fbbce2786cc, topicName=眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b85c13256921, createdName=pps20023, createdTime=Thu Jan 31 06:02:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602110, encodeId=7fd71602110f7, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Thu Jan 31 06:02:00 CST 2019, time=2019-01-31, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1668663, encodeId=d2d31668663a2, content=<a href='/topic/show?id=4929593e57f' target=_blank style='color:#2F92EE;'>#早期干预#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59375, encryptionId=4929593e57f, topicName=早期干预)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ab126374998, createdName=gao_jian4226, createdTime=Sun Apr 14 05:02:00 CST 2019, time=2019-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029876, encodeId=d57420298e614, content=<a href='/topic/show?id=fedde18245' target=_blank style='color:#2F92EE;'>#eye#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7182, encryptionId=fedde18245, topicName=eye)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Wed May 22 23:02:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913902, encodeId=fd87191390247, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sun Feb 10 07:02:00 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540519, encodeId=aedc1540519cd, content=<a href='/topic/show?id=fbbce2786cc' target=_blank style='color:#2F92EE;'>#眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72786, encryptionId=fbbce2786cc, topicName=眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b85c13256921, createdName=pps20023, createdTime=Thu Jan 31 06:02:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602110, encodeId=7fd71602110f7, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Thu Jan 31 06:02:00 CST 2019, time=2019-01-31, status=1, ipAttribution=)]
    2019-02-10 ysjykql
  4. [GetPortalCommentsPageByObjectIdResponse(id=1668663, encodeId=d2d31668663a2, content=<a href='/topic/show?id=4929593e57f' target=_blank style='color:#2F92EE;'>#早期干预#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59375, encryptionId=4929593e57f, topicName=早期干预)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ab126374998, createdName=gao_jian4226, createdTime=Sun Apr 14 05:02:00 CST 2019, time=2019-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029876, encodeId=d57420298e614, content=<a href='/topic/show?id=fedde18245' target=_blank style='color:#2F92EE;'>#eye#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7182, encryptionId=fedde18245, topicName=eye)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Wed May 22 23:02:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913902, encodeId=fd87191390247, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sun Feb 10 07:02:00 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540519, encodeId=aedc1540519cd, content=<a href='/topic/show?id=fbbce2786cc' target=_blank style='color:#2F92EE;'>#眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72786, encryptionId=fbbce2786cc, topicName=眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b85c13256921, createdName=pps20023, createdTime=Thu Jan 31 06:02:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602110, encodeId=7fd71602110f7, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Thu Jan 31 06:02:00 CST 2019, time=2019-01-31, status=1, ipAttribution=)]
    2019-01-31 pps20023
  5. [GetPortalCommentsPageByObjectIdResponse(id=1668663, encodeId=d2d31668663a2, content=<a href='/topic/show?id=4929593e57f' target=_blank style='color:#2F92EE;'>#早期干预#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59375, encryptionId=4929593e57f, topicName=早期干预)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ab126374998, createdName=gao_jian4226, createdTime=Sun Apr 14 05:02:00 CST 2019, time=2019-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029876, encodeId=d57420298e614, content=<a href='/topic/show?id=fedde18245' target=_blank style='color:#2F92EE;'>#eye#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7182, encryptionId=fedde18245, topicName=eye)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Wed May 22 23:02:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1913902, encodeId=fd87191390247, content=<a href='/topic/show?id=4684153e41f' target=_blank style='color:#2F92EE;'>#RET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15374, encryptionId=4684153e41f, topicName=RET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96d4340, createdName=ysjykql, createdTime=Sun Feb 10 07:02:00 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540519, encodeId=aedc1540519cd, content=<a href='/topic/show?id=fbbce2786cc' target=_blank style='color:#2F92EE;'>#眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72786, encryptionId=fbbce2786cc, topicName=眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b85c13256921, createdName=pps20023, createdTime=Thu Jan 31 06:02:00 CST 2019, time=2019-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602110, encodeId=7fd71602110f7, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Thu Jan 31 06:02:00 CST 2019, time=2019-01-31, status=1, ipAttribution=)]
    2019-01-31 sunylz

相关资讯

JAHA:步态速度与老年患者心脏手术后死亡率相关

在接受过心脏外科手术的老年人中,危险因素的预测很重要。本研究的目的旨在评估步态速度与1年死亡率和再住院风险的相关性。本研究纳入了8287名接受过心脏手术的患者,平均年龄74岁,女性占32%。1年后的生存率在慢速组(<0.83 m/s)、中速组(0.83–1.00 m/s)和快速组(>1.00 m/s)分别是90%、95%和97%,住院风险分别是45%、33%和27%(P<0.00

老年脑梗死急性期患者行急腹症手术一例麻醉处理

患者,女,72岁,身高157 cm,体重54kg。因“头晕、行走困难21h”于2016年10月12日入院。患者既往有高血压病史10余年。体格检查:T:37.2℃,P:100次/min,R:23次/min,BP:148/105mmHg,意识清楚,两侧瞳孔对等,对光反射灵敏,口齿含糊,额纹无变浅,鼻唇沟无变浅,口角无歪斜,伸舌居中,颈项强直(-)。右侧上肢肌力Ⅳ级,右侧下肢肌力Ⅲ级,右侧病理征阳性,左

病例分享:老年糖尿病患者血糖管理的困惑

21世纪是我国人口老龄化的快速进展时期。根据近5年全国调查数据推算,2017年中国老年(≥60岁)糖尿病患者约有5016万,随着老年人口总数的增加,这个人群还会扩大。

老年艾滋病患者,反复入院,毛病却越治越多

一位66岁的女性患者,来我院前半个月开始出现咳嗽、咳痰伴气促。患者有抑郁症及精神分裂症史,长期口服艾司西酞普兰、阿立哌唑控制。当地医院胸部CT示肺部感染,支气管镜提示支气管黏膜充血、水肿,可见较多脓性分泌物,予以三代头孢、莫西沙星抗感染治疗后症状略有缓解。

Stroke:老年睡眠呼吸暂停患者卒中发病率增加

由此可见,在未治疗的严重OSA的老年患者中,卒中发生率而非冠心病发病率有所增加。适当的CPAP治疗可以降低这种风险。

AGING CELL:不对称的皮质下可塑性与老年人的认知进展

已有的研究显示,结构性大脑不对称与认知有关。然而至今为止,我们尚不清楚神经心理学参数和结构偏侧性在多大程度上与衰老相关。